Phase II Study of Luspatercept in RBC Transfusion-Dependent Patients With Myelofibrosis-Associated Anemia: Updated Results

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
In this phase II study in patients with myelofibrosis-associated anemia and RBC transfusion dependence, luspatercept meaningfully improved transfusion independence with durable responses.
Format: Microsoft PowerPoint (.ppt)
File Size: 766 KB
Released: December 18, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Enter characteristics of your patient with myelodysplastic syndrome (MDS) into this online tool to receive treatment recommendations from 5 experts.

Rami S. Komrokji, MD
Program Director
Amy E. DeZern, MD, MHS Daniel Pollyea, MD, MS Michael J. Savona, MD Amer Zeidan, MBBS, MPH
Released: May 9, 2022

Experts answer HCP questions on myeloproliferative neoplasms (MPNs), from Clinical Care Options (CCO)

Prithviraj Bose, MD
Program Director
Stephen Oh, MD, PhD Brady L. Stein, MD, MHS
Released: May 3, 2022

Video from Clinical Care Options (CCO): Drs. Prithviraj Bose, Stephen Oh, and Brady Stein discuss key data on myeloproliferative neoplasms

Prithviraj Bose, MD Stephen Oh, MD, PhD Brady L. Stein, MD, MHS Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: April 21, 2022 Expired: April 20, 2023

Gain clinical insights quickly with this short slideset from Clinical Care Options (CCO) on treating patients with myeloproliferative neoplasms (MPNs)

Prithviraj Bose, MD Stephen Oh, MD, PhD Brady L. Stein, MD, MHS Released: March 2, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings